Legend Biotech (NASDAQ:LEGN) had its price target lowered by analysts at HC Wainwright from $60.00 to $50.00. They now have a "buy" rating on the stock.
Legend Biotech (NASDAQ:LEGN) was given a new $21.00 price target on by analysts at Jefferies Financial Group Inc..
Legend Biotech (NASDAQ:LEGN) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating.
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
Legend Biotech (NASDAQ:LEGN) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..